This bill mandates increased transparency, rigorous reporting, and audit requirements for pharmacy benefit managers (PBMs) operating within Medicare Part D and Medicare Advantage plans to help lower prescription drug costs for seniors.
Greg Landsman
Representative
OH-1
The Saving Seniors Money on Prescriptions Act increases transparency in Medicare Part D by requiring pharmacy benefit managers (PBMs) to provide detailed annual reports on drug pricing, rebates, and affiliate pharmacy practices. The bill mandates standardized reporting, grants plan sponsors robust audit rights, and ensures PBMs are held accountable for compliance. By shedding light on PBM operations, this legislation aims to lower prescription drug costs and improve oversight for Medicare beneficiaries.
New Medicare Rules Mandate PBM Transparency: Detailed Cost Reporting Starts in 2028.
The Saving Seniors Money on Prescriptions Act pulls back the curtain on Pharmacy Benefit Managers (PBMs)—the powerful middlemen who negotiate drug prices behind the scenes. Starting January 1, 2028, any PBM working with Medicare Part D or Medicare Advantage must provide a massive annual data dump to plan sponsors. This isn't just a basic summary; it’s a machine-readable breakdown of every drug dispensed, including the actual acquisition costs, total manufacturer rebates, and the exact out-of-pocket amounts enrollees paid. By forcing these companies to show their receipts, the bill aims to ensure that the discounts negotiated for seniors actually result in lower prices at the pharmacy counter.
Shining a Light on the Middleman
For years, PBMs have operated in a bit of a black box, but this bill changes the math. Under Section 2, PBMs must report the 'Average Wholesale Price' versus what they actually paid, along with every dollar they kept in 'bona fide service fees.' Think of it like your mechanic being forced to show you exactly what they paid for a car part before charging you a markup. For a retiree on a fixed income, this transparency could eventually lead to lower monthly premiums or copays because plan sponsors will finally see if their PBM is pocketing rebates that should have been used to lower costs. The bill also requires PBMs to use consistent definitions for terms like 'generic' and 'brand name,' preventing them from playing word games to meet pricing guarantees.
Leveling the Playing Field
One of the most relatable parts of this bill addresses 'affiliate pharmacies'—those retail or mail-order pharmacies owned by the same company as the PBM. The legislation requires PBMs to disclose if they are steering patients toward their own stores and to compare the costs of drugs at their pharmacies versus independent local shops. For a small-town pharmacist or a senior who prefers picking up meds in person rather than through a corporate mail-order program, this data is crucial. It exposes whether PBMs are charging Medicare more for drugs filled at their own affiliates, which could help protect local businesses and ensure patients aren't being nudged into a specific service just because it pads a PBM’s bottom line.
Accountability and the Fine Print
To make sure these aren't just empty requirements, the bill gives plan sponsors the right to audit PBMs at least once a year. If a PBM tries to hide data or misses a deadline, they are on the hook for any government fines the plan might face. While this is a big win for transparency, it’s worth noting the 'Medium' vagueness in how some data is handled; specifically, the bill includes strict confidentiality clauses that prevent the public from seeing specific drug prices to protect trade secrets. While your plan sponsor and the government will see the numbers, you won't be able to look up a PBM's exact profit on your specific bottle of insulin. However, the overall goal is clear: by giving the bosses at Medicare the tools to track every penny, the bill tries to squeeze the 'hidden' costs out of the system.